GlaxoSmithKline says Bexxar cancer drug gets strong support

GlaxoSmithKline PLC and Corixa Corp said a US Food and Drug Administration panel strongly supported their radioimmunotherapy drug Bexxar, which the two companies are jointly developing.

The FDA Oncologic Drugs Advisory Committee voted 10-3 in support of the efficacy of Bexxar therapy in treating some patients and unanimously supported its clinical use in low-grade and transformed low-grade non-Hodgkin's lymphoma, a form of cancer that affects the blood, bone marrow and lymphatic tissues.